Epigenome editing of the CFTR-locus for treatment of cystic fibrosis

Background: Mechanisms governing the diversity of CFTR gene expression throughout the body are complex. Multiple intronic and distal regulatory elements are responsible for regulating differential CFTR expression across tissues. Methods: Drawing on published data, 18 high-priority genomic regions were identified and interrogated for CFTR-enhancer function using CRISPR/dCas9-based epigenome editing tools. Each region was evaluated by dCas9(P300) and dCas9(KRAB) for its ability to enhance or repress CFTR expression, respectively. Results: Multiple genomic regions were tested for enhancer activity using CRISPR/dCas9 epigenome editing. dCas9(P300) mediates a significant increase in CFTR mRNA levels when targeted to the promoter and a region 44 kb upstream of the transcriptional start site in a CFTR-low expressing cell line. Multiple gRNAs targeting the promoter induced a robust increase in CFTR protein levels. In contrast, dCas9(KRAB)-mediated repression is much more robust with 10 of the 18 evaluated genomic regions inducing CFTR protein knockdown. To evaluate the therapeutic efficacy of modulating CFTR gene regulation, dCas9(P)(300) was used to induce elevated levels of CFTR from the endogenous locus in Delta F508/Delta F508 human bronchial epithelial cells. Ussing chamber studies demonstrated a synergistic increase in ion transport in response to CRISPR-induced expression of Delta F508 CFTR mRNA along with VX809 treatment. Conclusions: CRISPR/dCas9-based epigenome-editing provides a previously unexplored tool for interrogating CFTR enhancer function. Here, we demonstrate that therapeutic interventions that increase the expression of CFTR may improve the efficacy of CFTR modulators. A better understanding CFTR regulatory mechanisms could uncover novel therapeutic interventions for the development of cystic fibrosis therapies. (C) 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.